Baillieu crunches the numbers on White Rock

|

Published 11-SEP-2018 11:10 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

While commodity diversification is often seen as a positive attribute for both large and small miners, at times it can make asset valuations difficult.

This is very much the case with White Rock Minerals (ASX:WRM) which is developing the Red Mountain high grade zinc polymetallic project underway in Alaska, as well as the Mt Carrington gold-silver deposit in New South Wales.

White Rock is working towards establishing a JORC compliant resource for its Dry Creek and West Tundra Flats deposits at Red Mountain.

While this milestone event is some way off, the exploration grades already suggest that the company is well-positioned to establish a sizeable resource.

Red Mountain base valuation exceeds market capitalisation

Given that the company appears to be trading at a steep discount to its asset valuation, recent analysis conducted by Baillieu Holst’s Warren Edney is worth considering in terms of attributing a share price to the company.

Among other factors, he took into consideration both global and Australian peer comparisons, recent studies, exploration results and potential financing metrics in arriving at valuations for the Red Mountain and Mount Carrington projects.

Using the current zinc equivalent resource for White Rock as a base, Edney estimated that the implied value for Red Mountain is in a range between $28 million and $117 million.

It should be noted that broker projections and price targets are only estimates and may not be met. Those considering this stock should seek independent financial advice.

This valuation does not consider the economics of development, nor does it include the potential difference in prospectivity between other peers or the resource quality.

Regards the latter, the high base zinc grades and the compelling zinc equivalent grades taking into account silver, lead and gold credits are key distinguishing factors between the Red Mountain project and others that were cited by Edney.

It is worth noting that the base valuation of $28 million is more than double White Rock’s current market capitalisation.

Valuation of $22.8 million attributed to Mount Carrington

White Rock’s prefeasibility study Mount Carrington (PFS) generated free cash flow of $36.7 million and an internal rate of return IRR of 34% for Stage 1.

Using the details provide in the PFS, Edney modelled the cash flow from the development using the broker’s long-term commodity and currency forecasts – gold US$1300/ounce, silver US$20/ounce and an AUD/USD exchange rate of 75 cents.

His analysis generated a pre-tax ungeared net present value (NPV) of $22.8 million ($14.6 million on an after-tax basis).

This could represent a base case given that it does not include Stage 2 but would be a more robust proposition if the mine life was increased.

Consequently, using Edney’s base case metrics White Rock’s assets implied asset valuation is approximately $50 million, indicating that its shares are trading at a substantial discount.

In summing up the group’s prospects Edney said, “A combination of good board leadership, the option value of Mt Carrington and the exploration blue sky in Alaska makes WRM an interesting ASX exploration play and one that may get more attention following Northern Star’s acquisition of the Pogo mine in Alaska.”



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X